Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...

AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.

Nearly a decade after Erin Andrews was diagnosed with cervical cancer, the sportscaster told E! News she can't treat ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Yu Jianlong, vice chairman of CCPIT, said British enterprises, including Rio Tinto, AstraZeneca, HSBC, Swire, BP, and British ...

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.